Literature DB >> 10508410

Conformation of a rigid tetrasaccharide epitope in the capsular polysaccharide of Vibrio cholerae O139.

S Gunawardena1, C R Fiore, J A Johnson, C A Bush.   

Abstract

A newly reported strain of Vibrio cholerae, known as strain O139 Bengal, is the first instance of an encapsulated strain that has caused epidemic cholera. The O-antigenic capsule is the critical antigen for protective immunity. Since mapping of the antigenic epitopes will assist in the development of a protein conjugate vaccine based on the capsular polysaccharide, we have undertaken a study of the three-dimensional conformation of the polysaccharide. It contains six residues in the repeating subunit with the unusual feature of a 4,6 cyclic phosphate on a beta-galactopyranoside. A structural epitope composed of four of the residues is somewhat similar to the Lewis(b) blood group tetrasaccharide. Polysaccharide samples enriched in (13)C have been prepared by growth of the bacteria in (13)C-enriched medium. Multidimensional heteronuclear NMR and molecular modeling studies are reported, which show that the O139 tetrasaccharide adopts a compact and tightly folded conformation that is relatively rigid and similar to the Le(b) conformation. The cyclic phosphate on the beta-galactopyranoside residue is in contact with the colitose residue linked to the beta-GlcNAc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10508410     DOI: 10.1021/bi9910272

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  2 in total

1.  Vibrio cholerae O139 conjugate vaccines: synthesis and immunogenicity of V. cholerae O139 capsular polysaccharide conjugates with recombinant diphtheria toxin mutant in mice.

Authors:  Z Kossaczka; J Shiloach; V Johnson; D N Taylor; R A Finkelstein; J B Robbins; S C Szu
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

2.  Defining Polysaccharide-Specific Antibody Targets against Vibrio cholerae O139 in Humans following O139 Cholera and following Vaccination with a Commercial Bivalent Oral Cholera Vaccine, and Evaluation of Conjugate Vaccines Targeting O139.

Authors:  Mohammad Kamruzzaman; Meagan Kelly; Pavol Kováč; Peng Xu; Edward T Ryan; Richelle C Charles; Jason B Harris; Stephen B Calderwood; Aklima Akter; Rajib Biswas; M Hasanul Kaisar; Taufiqur R Bhuiyan; Louise C Ivers; Ralph Ternier; Jean-Gregory Jerome; Hélene B Pfister; Xiaowei Lu; Sameh E Soliman; Bart Ruttens; Rina Saksena; Jana Mečárová; Alžbeta Čížová; Firdausi Qadri; Slavomír Bystrický
Journal:  mSphere       Date:  2021-07-07       Impact factor: 4.389

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.